a-glucosidase

α-Glucosidase (α-D-Glucosidase) is a carbohydrate hydrolyzing enzyme that catalyzes the release of α-glucose from the non-reducing end of the substrate, playing a vital role in glucose absorption by the small intestine. Inhibiting α-Glucosidase effectively manages non-insulin-dependent diabetes mellitus (NIDDM).

α-Glucosidase-IN-23 is an orally active inhibitor of α-glucosidase that can decrease blood glucose levels by inhibiting α-glucosidase (IC50 = 4.48 μM).

α-Glucosidase-IN-22 is a selective inhibitor of α-glucosidase (IC50=0.64 μM). α-Glucosidase-IN-22 has antidiabetic activity and has potential in type 2 diabetes (T2DM) studies.

IHVR-17028 is a potent broad-spectrum ERα-glucosidase I (α-glucosidase I) inhibitor with IC50 of 0.24 μM and antiviral activity. IHVR-17028 inhibited BVDV, TCRV and DENV, and EC50 values were 0.4 μM, 0.26 μM and 0.3 μM, respectively. IHVR-17028 can be used to study infectious diseases.

Acarbose (BAY g 5421) is a hypoglycemic agent that is an inhibitor of orally active alpha-glucosidase (IC50=11 nM). Acarbose enhances the hypoglycemic effect of sulfonylureas or insulin.

Rebaudioside A (Reb A) is a novel agent of glycoside clathration of pharmacons, acts as α-glucosidase inhibitor.

1-Deoxynojirimycin (Moranoline) is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.

1. 3-Butylidenephthalide (Butylidene phthalide) has antihyperglycemic effect is due to inhibition of α-glucosidase at the intestinal level, inhibited the activity of yeast-α-glucosidase (IC(5) 2.35 mM) in a noncompetitive fashion with a K(i) of 4.86 mM.

Naringinase is a hydrolytic enzymatic complex that exhibits α-L-rhamnosidase and β-D-glucosidase activities. It is widely found in nature and is primarily utilized for the biotransformation of steroids, antibiotics, and glycosides.

(E)-3-(4-Methoxyphenyl)acrylic acid is a small molecule compound isolated from the rhizome of Etlingera pavieana (Pierre ex Gagnep.) R. M. Sm. It is a novel α-glucosidase inhibitor with hepatoprotective, antiamnesic, and cognitive enhancement activities, and it can be used to lower blood pressure sugar.

α-Glucosidase-IN-4 is a potent α-glucosidase inhibitor exhibiting antihypertensive and hypoglycemic activity.

Ceftezole is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity. It is a broad-spectrum cephem antibiotic against many species of gram-positive and gram-negative bacteria.

Glycosidase-IN-1 is a glycosidase inhibitor synthesized from D-mannose with hypoglycemic activity. It can be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors.

Chrysanthellin B exhibits beta-glucosidase inhibition that is approximately five times lower than that of acarbose but remains significant. Chrysanthellin B is therefore used in enzymology and carbohydrate metabolism research systems to investigate glycosidase inhibition profiles, enzyme–substrate interaction dynamics, and comparative inhibitor potency in glucosidase-related biochemical assays.

Vitexin 2''-glucoside (Flavosativaside) is a potent and selective alpha-glucosidase inhibitor found in hawthorn leaf flavonoids. Vitexin 2''-glucoside reversibly inhibits α-glucosidase activity on the brush border of the small intestine, with stronger inhibitory activity than acarbose. Vitexin 2''-glucoside is utilized in biomedical research focused on carbohydrate metabolism regulation, intestinal enzymatic activity, and glucose absorption pathway studies relevant to metabolic disease models.

Terphenyllin has α-glucosidase inhibitory activity, and is a natural product isolated from the coral derived fungus Aspergillus candidus.

Choerospondin, a dietary flavonoid glycoside isolated from the bark of the southern date palm (Ziziphus jujuba L.), is a potential α-glucosidase inhibitor with antiproliferative, antioxidant, antitumor, and anti-inflammatory activities that enhances the resistance to oxidative stress, and significantly inhibits inflammatory responses by attenuating mitogen-activated protein kinase phosphorylation and nuclear factor-κ B activation.

IHVR-19029 is an effective endoplasmic reticulum (ER) α-glucosidases I and II inhibitor (IC50: 0.48 μM for ER a-glucosidase I). IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Ebola virus, Dengue virus, and Rift

Afegostat is a pharmacological chaperone that specifically and reversibly binds acid-β-glucosidase (GCase) in the endoplasmic reticulum with high affinity.

Afegostat D-Tartrate is a pharmacological chaperone that binds specifically and reversibly with high affinity to acid-β-glucosidase (GCase) in the endoplasmic reticulum.

α-Glucosidase-IN-72 (compound 5i), a 2,4-dichloro-N-phenylacetamide derivative, functions as an α-glucosidase inhibitor with an inhibitory concentration (IC 50) of 6 μM. Notably, it does not adhere to Lipinski's "rule of five" and is not a cancer inducer.

SX29 is a non-competitive α-glucosidase inhibitor with oral activity, exhibiting an IC50 of 2.12 μM. It possesses hypoglycemic properties; oral administration of SX29 reduces blood glucose levels and enhances glucose tolerance in diabetic mice.

α-Glucosidase-IN-74, a nicotinamide-thiazole derivative, functions as an α-glucosidase (α-glucosidase) inhibitor. It demonstrates antidiabetic activity by reducing blood glucose and triglyceride levels in Streptozotocin-induced diabetic animals.

α-Glucosidase/NLRP3-IN-1 (Compound 8) acts as a dual inhibitor targeting both α-glucosidase and NLRP3. It features an IC50 value of 6.6 μM for α-glucosidase and inhibits NLRP3 across multiple cell lines at a concentration of 100 μM. This compound demonstrates neuroprotective and antidiabetic properties, making it suitable for related research.